查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球管道成形术治疗市场 -2023-2030
市场调查报告书
商品编码
1374785

全球管道成形术治疗市场 -2023-2030

Global Canaloplasty Treatment Market -2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

泪管成形术是一种用于治疗青光眼的外科手术，青光眼是一组以眼内压 (IOP) 升高为特征的眼部疾病，可损害视神经并导致视力丧失。泪管成形术的主要目标是降低升高的眼压，眼压是青光眼视神经损伤和进行性视力丧失的主要危险因子。透过疏通和扩大眼睛的自然排水系统，管道成形术可以有效降低眼压并帮助保护视力。

管道成形术带来的持久眼压降低可以帮助患者避免或推迟进一步的手术，并减少频繁调整药物的需要。对于各种个体，包括那些患有轻度至中度开角型青光眼、尚未通过药物缓解并正在寻找手术选择的患者，眼管成形术可能是一种有效的治疗方法。想要减少与更具侵入性的手术相关的危险的患者也可以选择它。

市场动态：驱动因素与限制因素

公司采取的策略

该公司的产品发布和产品技术开发等策略加速了市场成长。例如，2022 年 4 月，Nova Eye Medical Limited 在一些欧洲和亚洲地区提供下一代管道成形术设备 iTrack Advance地区。 iTrack Advance 的推出表明了我们致力于扩大管道成形术领域的决心。该公司预计 iTrack Advance 的发布将导致白内障外科医生和普通眼科医生进行眼管成形术的数量增加。

推动全球血管成形术市场收入成长的主要因素之一是青光眼病例的增加。青光眼患者的数量呈现週期性增加，因为这种疾病是一种无痛眼部疾病，直到视力严重丧失时才会出现症状。因此，上述因素推动了市场的成长。

市场动态：克制

管道成形术有许多积极作用，但也有一些因素可能阻碍其广泛使用或限制其在特定情况下的应用。例如，管道成形术是一种敏感的治疗方法，要求外科医生具有高水准的能力和经验。

并非所有眼外科医生都熟练使用该技术，并且与许多其他复杂的手术治疗一样，该技术的成本可能很高，这可能限制了患者对眼管成形术的可用性。特别是在医疗保健覆盖不足或患者必须自掏腰包进行医疗手术的地区或国家，费用可能是关键的影响因素。

目录

第 1 章：方法与范围

  • 研究方法论
  • 报告的研究目的和范围

第 2 章：定义与概述

第 3 章：执行摘要

  • 按类型分類的片段
  • 手术技术片段
  • 最终使用者的片段
  • 按地区分類的片段

第 4 章：动力学

  • 影响因素
    • 司机
      • 青光眼疾病的兴起
      • 公司采取的策略
  • 限制
      • 与治疗相关的高费用
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • DMI 意见

第 6 章：COVID-19 分析

  • COVID-19 分析
    • 新冠疫情爆发前的情景
    • 新冠疫情期间的情景
    • 新冠疫情后的情景
  • COVID-19 期间的定价动态
  • 供需谱
  • 疫情期间政府与市场相关的倡议
  • 製造商策略倡议
  • 结论

第 7 章：按类型

  • 传统管道成形术
  • 微导管辅助管道成形术

第 8 章：透过手术技术

  • 经内管成形术
  • 体外管道成形术

第 9 章：按最终用户

  • 眼科诊所
  • 医院
  • 其他的

第 10 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 亚太其他地区
  • 中东和非洲

第 11 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 12 章：公司简介

  • Nova Eye Medical Limited
    • 公司简介
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • Ellex Medical Lasers
  • Haag-Streit
  • New World Medical
  • Sight Sciences
  • Glaukos Corporation
  • Ophthalmic Instruments Pte Ltd.
  • New World Medical, Inc
  • Ohio Eye Alliance
  • iScience Interventional

第 13 章：附录

简介目录
Product Code: MD7193

Overview

Canaloplasty is a surgical procedure used to treat glaucoma, a group of eye conditions characterized by increased intraocular pressure (IOP) that can damage the optic nerve and lead to vision loss. The primary goal of canaloplasty is to lower elevated IOP, which is a major risk factor for optic nerve damage and progressive vision loss in glaucoma. By unblocking and widening the eye's natural drainage system, canaloplasty can effectively reduce IOP and help preserve vision.

Long-lasting IOP reduction from canaloplasty can help patients avoid or delay further procedures and lessen the need for frequent medication modifications. For a variety of individuals, including those with mild to moderate open-angle glaucoma who have not found relief from medication and are searching for a surgical option, canaloplasty may be an effective course of treatment. Patients who want to reduce the dangers connected with more invasive surgeries can additionally opt for it.

Market Dynamics: Drivers and Restraints

The strategies adopted by the companies

The strategies like product launches and technological developments of the products by the companies which accelerates the market growth.For instance, in April 2022, Nova Eye Medical Limited is offering the iTrack Advance, a next-generation canaloplasty device, in a few European and Asian regions. The launch of the iTrack Advance demonstrates our dedication to expanding the canaloplasty sector. The company anticipates that the release of iTrack Advance will lead to an increase in the number of cataract surgeons and general ophthalmologists performing canaloplasty procedures.

One of the main factors propelling the growth of the worldwide canaloplasty market's revenue is the rise in glaucoma cases. The number of glaucoma patients is cyclically increasing because the condition is a painless eye ailment that does not cause symptoms until there is considerable vision loss. Thus above factors boost the market growth.

Market Dynamics: Restraint

Canaloplasty has a number of positive effects but there are also certain things that can prevent it from being widely used or limit its application in specific circumstances. For instance, canaloplasty is a sensitive treatment that demands a surgeon to have a high level of competence and experience.

The availability of canaloplasty to patients may be constrained by the fact that not all eye surgeons are skilled in using this technique, and it can be costly, like many other sophisticated surgical treatments. Particularly in areas or nations with inadequate healthcare coverage or where patients must pay out-of-pocket for medical operations, the cost may be a crucial influencing factor.

Segment Analysis

The global canaloplasty treatment market is segmented based on type, surgical techniques, end-user and region.

The microcatheter-assisted canaloplasty segment from the type segment accounted for approximately 41.7% of canaloplasty treatment share

Microcatheter-assisted canaloplasty is a minimally invasive procedure. It avoids the need for major incisions and reduces trauma to the eye. This minimizes post-operative discomfort and promotes faster recovery compared to traditional, more invasive glaucoma surgeries. Ongoing advancements in microcatheter technology and surgical techniques continue to refine and improve the outcomes of microcatheter-assisted canaloplasty, making it an increasingly viable option for glaucoma patients.

Additionally, the novel products helps to accelerates the segment growth. For instance, in March 2021, Sight Sciences, Inc., a growth-stage Medical Device company focused on addressing the underlying causes of the world's most common eye conditions, the OMNI Surgical System (OMNI) had approved USFDA 510(k) clearance for canaloplasty (microcatheterization and transluminal vasodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce Intraocular Pressure (IOP). Thus above factors boost the segment growth.

Geographical Analysis

North America Accounted for Approximately 38.4% of the Market Share in 2022

North America is expected to account for the largest revenue share over the forecast period. Leading market players' presence, efficient reimbursement policies, and public health programs such as Eye America and rise of glaucoma helps to boost the region growth. For instance, according to CDC, a series of illnesses known as glaucoma harm the optic nerve in the eye, which can lead to vision loss and even blindness.

Glaucoma affects about 3 million Americans. It is the second most common cause of blindness in the globe. The most prevalent type of glaucoma, open-angle glaucoma, causes an increase in ocular pressure. Since glaucoma frequently has no early symptoms, 50% of those who have it are unaware that exist. Due to improvements in healthcare infrastructure, rising disposable income, the established presence of domestic companies in the region, the availability of glaucoma surgery devices, healthcare reforms, and technological advancements, Asia Pacific is predicted to experience significant revenue over the forecast period.

COVID-19 Impact Analysis

Restrictions and safety concerns initially limited patient access to treatment centers. Yet, as restrictions relaxed, there was a noticeable market recovery, emphasizing minimally invasive procedures and a rise in telemedicine consultations. Manufacturers and healthcare providers adjusted to the new circumstances by enforcing rigorous safety measures. The market's progress is steadily improving as healthcare systems stabilize and patient confidence rebounds. Future growth is fueled by innovation and a patient-focused approach.

Competitive Landscape

The major global players in the market include: Nova Eye Medical Limited, Ellex Medical Lasers, Haag-Streit, New World Medical, Sight Sciences, Glaukos Corporation, Ophthalmic Instruments Pte Ltd., New World Medical, Inc, Ohio Eye Alliance, iScience Interventional and among others.

Key Developments

  • In November 10, 2021, the Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) authorising the company to conduct a clinical study to evaluate the safety and effectiveness of a new, higher volume, investigational OMNI device ("higher volume OMNI") to perform canal viscodilation alone to lower intraocular pressure. Sight Sciences, Inc. is an eyecare technology company focused on developing innovative solutions intended to transform standards of care and improve patients' lives.

Why Purchase the Report?

  • To visualize the global canaloplasty treatment market segmentation based on type, surgical techniques, end-user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of canaloplasty treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global canaloplasty treatment market report would provide approximately 61 tables, 63 figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Surgical Techniques
  • 3.3. Snippet by End-user
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rise of glaucoma diseases
      • 4.1.1.2. The strategies adopted by the companies
  • 4.2. Restraints
      • 4.2.1.1. High cost associated with the treatment
    • 4.2.2. Opportunity
    • 4.2.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Traditional Canaloplasty *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Microcatheter-assisted Canaloplasty

8. By Surgical Techniques

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgical Techniques
    • 8.1.2. Market Attractiveness Index, By Surgical Techniques
  • 8.2. Ab-interno canaloplasty *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Ab-externo canaloplasty

9. By End-user

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 9.1.2. Market Attractiveness Index, By End-user
  • 9.2. Ophthalmology clinics *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Hospitals
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgical Techniques
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgical Techniques
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgical Techniques
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgical Techniques
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgical Techniques
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Nova Eye Medical Limited *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Ellex Medical Lasers
  • 12.3. Haag-Streit
  • 12.4. New World Medical
  • 12.5. Sight Sciences
  • 12.6. Glaukos Corporation
  • 12.7. Ophthalmic Instruments Pte Ltd.
  • 12.8. New World Medical, Inc
  • 12.9. Ohio Eye Alliance
  • 12.10. iScience Interventional

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us